Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry's responsibility to maintain scientific integrity.

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma.

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...